Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Active not recruiting 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Myeloid 5CNS 4Sarcoma 3Plasma cell 3Other hematologic neoplasm 3Thoracic 2Lymphoid 2Breast 2Gastrointestinal 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocytosis 1Thrombocythemia, Essential 1Recurrence 1Polycythemia Vera 1Polycythemia 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 259fludarabine phosphate 232Azacitidine 180fludarabine 179Busulfan 174Cytarabine 154Mycophenolic Acid 147Tacrolimus 145Whole-Body Irradiation 141Imatinib Mesylate 141Peripheral Blood Stem Cell Transplantation 139Cyclosporine 110Antilymphocyte Serum 108Melphalan 106Methotrexate 105Filgrastim 101Decitabine 98nilotinib 82venetoclax 77ruxolitinib 72Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 62Dasatinib 62Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × imetelstat × Myeloid × Clear all
NCT05583552 2026-05-12

IMpress

GCP-Service International West GmbH

Phase 2 Active not recruiting
46 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting
289 enrolled 35 charts 1 FDA
Myeloid

Myelodysplastic Syndromes, Recurrence

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Geron Corporation

Phase 3 Active not recruiting
327 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Geron Corporation

Phase 2 Completed
80 enrolled 31 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01243073 2016-01-26

ET/PV

Geron Corporation

Phase 2 Completed
20 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡